Clinical Research Trials : Hepatitis D

Hepatitis D

1. EIG-LNF-011: A Phase 3, Matrix Design, Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 weeks Compared to PEG IFN alfa-2a Monotherapy and to No Treatment in Patients Chronically Infected with Hepatitis Delta Virus being Maintained on anti-HBV Nucleos(t)ide Therapy.

  • Status: Open
  • PI: Eugene Schiff
  • Coordinator: Katheryn Dae
  • Contact: (305) 243-1104 / kqd1@med.miami.edu